Nivolumab (anti-PD-1), 1mg

Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1)with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.